Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Multicenter, Double-Masked, Randomized, Parallel-Group Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age-Related Macular Degeneration (nAMD)

NCT06223958 is registered in ClinicalTrials.gov with Ocular Therapeutix, Inc. as lead sponsor.

NCT NCT06223958
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06223958 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Multicenter, Double-Masked, Randomized, Parallel-Group Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age-Related Macular Degeneration (nAMD)
Lead sponsor
Ocular Therapeutix, Inc.
Phase
Phase 3
Overall status
Active, not recruiting
Start date
January 29, 2024
Completion date
September 27, 2027
Enrollment
344 (actual)
Sites
108

Conditions

As the registry lists them; a condition with its own page is linked.

neovascular age-related macular degeneration